Moleculin Biotech rises as cancer drug shows no heart damage in trials
ReutersJan 13, 2026 2:09 PM
Shares of drug developer Moleculin Biotech MBRX.O rise 2.2% to $4.14 premarket
Co says its experimental cancer drug, annamycin, showed no signs of causing heart damage in patients in five clinical trials
Independent expert reviewed data from 90 patients with leukemia and sarcoma; found no heart issues - MBRX
Annamycin, also called naxtarubicin, tested for leukemia and sarcoma spread
Leukemia is a blood cancer; sarcoma is a cancer that starts in soft tissues and can spread to lungs
Drug being studied alone and with chemotherapy; late-stage leukemia trial ongoing - MBRX
Co says it is working to secure funding and will monitor patients long-term for heart issues
As of last close, stock down ~92% over the past year
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.TradingKey
10 hours ago
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).TradingKey
10 hours ago
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
